These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

82 related articles for article (PubMed ID: 18595548)

  • 1. Update on infectious disease prevention: human papillomavirus, hepatitis A.
    Longworth DL
    Cleve Clin J Med; 2008 Jun; 75(6):402-3, 409-10. PubMed ID: 18595548
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Quadrivalent Human Papillomavirus Vaccine: Recommendations of the Advisory Committee on Immunization Practices (ACIP).
    Markowitz LE; Dunne EF; Saraiya M; Lawson HW; Chesson H; Unger ER; ;
    MMWR Recomm Rep; 2007 Mar; 56(RR-2):1-24. PubMed ID: 17380109
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [AN HPV-ASSOCIATED DISEASES AND CERVICAL CANCER AND PROPHYLACTIC HUMAN PAPILLOMAVIRUS (HPV) VACCINES].
    Malinova M
    Akush Ginekol (Sofiia); 2015; 54 Suppl 1():25-31. PubMed ID: 26137767
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Reduced dose human papillomavirus vaccination: an update of the current state-of-the-art.
    Toh ZQ; Licciardi PV; Fong J; Garland SM; Tabrizi SN; Russell FM; Mulholland EK
    Vaccine; 2015 Sep; 33(39):5042-50. PubMed ID: 26271829
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Broad-spectrum human papillomavirus vaccines: new horizons but one step at a time.
    Bosch FX
    J Natl Cancer Inst; 2009 Jun; 101(11):771-3. PubMed ID: 19470950
    [No Abstract]   [Full Text] [Related]  

  • 6. An overview of human papillomavirus infection for the dermatologist: disease, diagnosis, management, and prevention.
    Forcier M; Musacchio N
    Dermatol Ther; 2010; 23(5):458-76. PubMed ID: 20868401
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Nine-valent HPV vaccine - new generation of HPV vaccine].
    Fait T; Dvořák V; Pilka R
    Ceska Gynekol; 2015 Dec; 80(6):397-400. PubMed ID: 26741152
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Update: Recommendations of the Advisory Committee on Immunization Practices for Use of Hepatitis A Vaccine for Postexposure Prophylaxis and for Preexposure Prophylaxis for International Travel.
    Nelson NP; Link-Gelles R; Hofmeister MG; Romero JR; Moore KL; Ward JW; Schillie SF
    MMWR Morb Mortal Wkly Rep; 2018 Nov; 67(43):1216-1220. PubMed ID: 30383742
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [The first vaccine against cancer: the human papillomavirus vaccine].
    Bősze P
    Orv Hetil; 2013 Apr; 154(16):603-18. PubMed ID: 23587540
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Human papillomavirus vaccine: recommendations, issues and controversies.
    Fisher R; Darrow DH; Tranter M; Williams JV
    Curr Opin Pediatr; 2008 Aug; 20(4):441-5. PubMed ID: 18622201
    [TBL] [Abstract][Full Text] [Related]  

  • 11. New quadrivalent HPV vaccine developments.
    Tovar JM; Bazaldua OV
    Postgrad Med; 2008 Nov; 120(4):14-6. PubMed ID: 19020361
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Epidemiological dynamic modeling of human papillomavirus-related diseases to assess vaccination strategies in Argentina.
    Borracci RA; Segal SV; Méndez JH
    Medicina (B Aires); 2018; 78(5):315-328. PubMed ID: 30285924
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Spotlight on quadrivalent human papillomavirus (types 6, 11, 16, 18) recombinant vaccine(Gardasil®) in the prevention of premalignant genital lesions, genital cancer, and genital warts in women.
    McCormack PL; Joura EA
    BioDrugs; 2011 Oct; 25(5):339-43. PubMed ID: 21942919
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [To prevent HPV-associated neoplasia].
    Gross G
    Dtsch Med Wochenschr; 2014 Aug; 139(31-32):1605. PubMed ID: 25076317
    [No Abstract]   [Full Text] [Related]  

  • 15. Human papillomavirus quadrivalent vaccine: a look behind the numbers.
    Flaherty DK; Alkhateeb FM
    Ann Pharmacother; 2009 Apr; 43(4):740-4. PubMed ID: 19276314
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The cost-effectiveness of a quadrivalent human papillomavirus vaccine in Taiwan.
    Dasbach EJ; Insinga RP; Yang YC; Pwu RF; Lac C; Elbasha EH
    Asian Pac J Cancer Prev; 2008; 9(3):459-66. PubMed ID: 18990021
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical perspectives on the role of the human papillomavirus vaccine in the prevention of cancer.
    Julius JM; Ramondeta L; Tipton KA; Lal LS; Schneider K; Smith JA
    Pharmacotherapy; 2011 Mar; 31(3):280-97. PubMed ID: 21361739
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cost-effectiveness of HPV vaccination in the context of high cervical cancer incidence and low screening coverage.
    Võrno T; Lutsar K; Uusküla A; Padrik L; Raud T; Reile R; Nahkur O; Kiivet RA
    Vaccine; 2017 Nov; 35(46):6329-6335. PubMed ID: 28899625
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cervical cancer prevention in the era of prophylactic vaccines: a preview for gynecologic oncologists.
    ; Collins Y; Einstein MH; Gostout BS; Herzog TJ; Massad LS; Rader JS; Wright J
    Gynecol Oncol; 2006 Sep; 102(3):552-62. PubMed ID: 16979432
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical cancer chemoprevention: From the hepatitis B virus (HBV) vaccine to the human papillomavirus (HPV) vaccine.
    Tsai HJ
    Taiwan J Obstet Gynecol; 2015 Apr; 54(2):112-5. PubMed ID: 25951712
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.